Global RNA Based Therapeutic Market Size, Share & Industry Trends Analysis Report By Type (RNA Antisense and RNA Interference (RNAi)), By Application, By End User, By Regional Outlook, Strategy, Challenges and Forecast, 2021 - 2027

The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1 % CAGR during the forecast period.

RNA-based treatments have received a lot of popularity in recent years because of their potential to cure a wide range of chronic diseases like cancer, diabetes, AIDS, tuberculosis, and certain cardiovascular ailments, as well as uncommon and hereditary abnormalities. RNA-based treatments have been investigated as a viable treatment option for difficult-to-treat disorders, despite being in the clinical development phase.

The therapies are being developed using promising technologies such as RNA interference (RNAi), antisense technology, and SMaRT technology. RNAi and antisense technology are gaining popularity in the research business because they give the base sequence for developing RNA therapeutics. The potential for RNA to be employed for therapeutic purposes has been explored, and specific problems have arisen during drug discovery and the implementation of RNA therapies.

COVID-19 Impact Analysis

Coronavirus (COVID-19) was discovered in Wuhan, Hubei Province, China, in December 2019. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which can be rapidly spread between people. Moreover, this virus causes a variety of symptoms in individuals, ranging from minor to severe fever, dry cough, and exhaustion. These are some of the most prevalent symptoms. Breathing difficulties or shortness of breath, chest pain or pressure, and lack of speech or movement are all dangerous signs.

In addition, among the older population, the virus has a high risk of causing death. The World Health Organization (WHO) has declared COVID-19 a pandemic as of March 11, 2020. Furthermore, only a few vaccines have been licensed for COVID-19 in the event of an emergency.

Market Growth Factors:

An increasing number of chronic diseases and disorders

Demand is fueled by the presence of a large number of patients with infectious and chronic diseases. The desire for cures for infectious diseases and cancer is projected to influence the growth of the global RNA-based therapies and vaccine market. Moreover, according to the data shared by the WHO, Cancer is the second biggest cause of death worldwide, accounting for 9.6 million fatalities in 2018, or one in every six deaths. Men's cancers include lung, colorectal, stomach, prostate, and liver cancer, whereas women's cancers include breast, lung, cervical, colorectal, and thyroid cancer.In addition, the patient pool is large, which is expected to be another growth factor for the worldwide RNA-based therapies and vaccine market in the approaching years.

The rising popularity of personalized medicines

A large number of people are currently undergoing various drug courses as a result of a broad range of disorders. The remedies are made with a variety of salts and other ingredients and are intended for broad use. Regular drugs are supplied to clients in accordance with their treatment needs. Acids and salts, as well as other ingredients found in generic treatments, are not suitable for everyone. Due to RNA-based therapeutic, the practitioners are allowed to provide patients with personalized medicines based on their bodies' needs.

Marketing Restraining Factor:

Obstacles in the delivery of mRNA

Because mRNA is such a massive and hefty molecule (105 106 Da), successfully translating it into pharmaceuticals poses numerous problems. Additionally, mRNA is unstable and susceptible to nuclease degradation, as well as activating the immune system. In addition, because mRNA has a large negative charge density, it is less permeable across cell membranes. Because of these factors, mRNA is easily destroyed in the absence of a suitable delivery method, with a half-life of only around 7 hours. Despite the fact that chemical changes have helped to overcome some obstacles, mRNA delivery remains a challenge. Microinjection, RNA patches (mRNA loaded in a dissolving micro-needle), gene gun, protamine condensation, RNA adjuvants, and encapsulating mRNA in nanoparticles with lipids are some of the approaches that have been studied to increase mRNA delivery.

Type Outlook

Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). The RNA antisense segment dominated the RNA-based therapeutics market by acquiring the largest revenue share. The growth of this segment is attributed to its property of treating multiple diseases. Antisense RNA is utilized in cancer treatment, metastasis inhibition, and antisense sequestration vectors.

Application Outlook

Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. The autoimmune disorders segment accounted for significant revenue share. A disorder in which the immune system accidentally targets the body itself is known as autoimmune disease. Normally, the immune system protects us against pathogens such as bacteria and viruses.

End User Outlook

Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. The research institutes segment dominated the market by accounting for the largest revenue share. Due to the increasing number of collaborations between research organizations and academic research institutions or cooperating with government agencies in order to bear the high cost of research, the research institutes segment observed an accelerated growth.

RNA Based Therapeutic Market Report Coverage

Report Attribute	Details
Market size value in 2020	USD 4.7 Billion
Market size forecast in 2027	USD 11.4 Billion
Base Year	2020
Historical Period	2017 to 2019
Forecast Period	2021 to 2027
Revenue Growth Rate	CAGR of 15.1% from 2021 to 2027
Number of Pages	182
Number of Tables	323
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling
Segments covered	Type, Application, End User, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	An increasing number of chronic diseases and disorders The rising popularity of personalized medicines
Restraints	Obstacles in the delivery of mRNA

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America dominated the market by accounting for the largest revenue share. Research efforts for RNA-based treatments are expected to increase in North America as a result of a strong infrastructure for developmental research, the availability of substantial research funds, and increased government initiatives toward RNA-based medicines.

Free Valuable Insights: Global RNA Based Therapeutic Market size to reach USD 11.4 Billion by 2027

KBV Cardinal Matrix - RNA Based Therapeutic Market Competition Analysis

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Sanofi S.A. is the major forerunner in the RNA Based Therapeutic Market. Companies such as Alnylam Pharmaceuticals Inc., Biogen, Inc., Arbutus Biopharma Corporation are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.

Recent Strategy Deployed in RNA Based Therapeutic Market

» Partnerships, Collaborations and Agreements:

• Jan-2022: Alnylam Pharmaceuticals collaborated with Novartis for exploring whether the Cambridge, Massachusetts-based biotech company's RNA technology can be utilized for helping restore function in liver failures. The collaboration focused on identifying a potential treatment alternative for organ transplant patients with liver disease's end-stage.
• Dec-2021: Arbutus Biopharma signed licensing agreement and strategic partnership with Qilu Pharmaceuticals, one of the leading pharmaceutical companies in China. The agreement aimed to develop and commercialize AB-729 for treating and preventing hepatitis B in mainland China, Macau, Hong Kong, and Taiwan.
• Nov-2021: Arrowhead Pharmaceuticals came into an exclusive license agreement with GlaxoSmithKline. Under this agreement, GSK develops and commercializes ARO-HSD, Arrowhead's investigational RNAi therapeutics in a Phase 1/2 trial. Currently, this is being developed as a treatment for patients with nonalcoholic steatohepatitis.
• Oct-2021: Silence Therapeutics entered into a partnership with Hansoh Pharmaceuticals for developing small-interfering ribonucleic acid (siRNAs) drugs for three undisclosed targets by leveraging the former’s mRNAi GOLD platform. The partnership allowed the former company to move its two proprietary programmes forward subsidized by non-dilutive capital while also gaining access to the second-largest pharmaceutical market globally.
• Jul-2021: Biogen teamed up with Mirimus, a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene-editing technology implementation. The collaboration was aimed to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. Additionally, the latter company would apply its expertise in engineering RNAi-based therapeutics that would be assessed by the former company for determining feasibility in potential neurological disease settings.
• Jun-2021: Arrowhead Pharmaceuticals announced a partnership and licensing agreement with Horizon Therapeutics. The partnership aimed to create the Arrowhead's ribonucleic acid interference (RNAi) therapeutic, ARO-XDH. This is an experimental short interfering RNA therapy and targets xanthine dehydrogenase.
• Jun-2021: Arbutus Biopharma signed a clinical collaboration agreement with Antios Therapeutics. The agreement was signed for evaluating the triple combination of Arbutus' proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread (tenofovir disoproxil fumarate), for the treatment of patients with chronic hepatitis B virus infection.
• May-2021: Biogen signed a collaboration agreement with Envisagenics for the advancement of ribonucleic acid (RNA) splicing research in central nervous system (CNS) diseases. Moreover, Biogen would utilize the latter company's proprietary AI-driven RNA splicing platform, SpliceCore for defining and understanding the regulation of various RNA isoforms in CNS cell types.
• Oct-2020: Arrowhead Pharmaceuticals came into a collaboration and licensing agreement with Takeda Pharmaceutical. The collaboration was focused on creating ARO-AAT, a Phase 2 investigational RNA interference therapy for the treatment of alpha-1 antitrypsin-associated liver disease (AATLD).
• Jun-2020: Sarepta Therapeutics announced an agreement with Codiak BioSciences, a company at the forefront of advancing engineered exosomes. The agreement was focused on designing and developing engineered exosome therapeutics for providing gene editing, gene therapy, and RNA technologies for neuromuscular diseases.
• Apr-2020: Alnylam Pharmaceuticals teamed up with Blackstone following which the latter company offers up to $2 billion for supporting the former company's advancements of innovative RNA interference medicines.

» Approvals and Trials:

• Dec-2021: Alnylam Pharmaceuticals announced that it got FDA approval for its Leqvio for lowering low-density lipoprotein cholesterol. This RNAi therapeutic is indicated for the treatment of a major risk factor for highly prevalent disease.

» Acquisitions, Mergers and Joint Ventures:

• Aug-2021: Sanofi announced an agreement to acquire Translate Bio, a clinical-stage mRNA therapeutics company. The acquisition would add mRNA technology platform and capabilities to the company's research and would advance its ability to explore the technology to create best-in-class therapeutics and vaccines.
• Apr-2021: Sanofi took over Tidal Therapeutics, a pre-clinical stage biotech company. The addition of new technology platform expanded Sanofi's research capabilities in inflammatory and immuno-oncology diseases and can apply to other diseases areas.

Scope of the Study

Market Segments Covered in the Report:

By Type

• RNA Antisense
• RNA Interference (RNAi)

By Application

• Genetic disorders
• Auto immune disorders

By End User

• Research Institutes
• Hospitals & Clinics

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma, Inc.
• Alnylam Pharmaceuticals, Inc.
• Sanofi S.A. (Sanofi Genzyme)
• Biogen, Inc.
• Gradalis, Inc.
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Silence Therapeutics Plc

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global RNA Based Therapeutic Market, by Type
1.4.2 Global RNA Based Therapeutic Market, by Application
1.4.3 Global RNA Based Therapeutic Market, by End User
1.4.4 Global RNA Based Therapeutic Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players

Chapter 4. Global RNA Based Therapeutic Market by Type
4.1 Global RNA Antisense Market by Region
4.2 Global RNA Interference (RNAi) Market by Region

Chapter 5. Global RNA Based Therapeutic Market by Application
5.1 Global Genetic disorders Market by Region
5.2 Global Auto immune disorders Market by Region

Chapter 6. Global RNA Based Therapeutic Market by End User
6.1 Global Research Institutes Market by Region
6.2 Global Hospitals & Clinics Market by Region

Chapter 7. Global RNA Based Therapeutic Market by Region
7.1 North America RNA Based Therapeutic Market
7.1.1 North America RNA Based Therapeutic Market by Type
7.1.1.1 North America RNA Antisense Market by Country
7.1.1.2 North America RNA Interference (RNAi) Market by Country
7.1.2 North America RNA Based Therapeutic Market by Application
7.1.2.1 North America Genetic disorders Market by Country
7.1.2.2 North America Auto immune disorders Market by Country
7.1.3 North America RNA Based Therapeutic Market by End User
7.1.3.1 North America Research Institutes Market by Country
7.1.3.2 North America Hospitals & Clinics Market by Country
7.1.4 North America RNA Based Therapeutic Market by Country
7.1.4.1 US RNA Based Therapeutic Market
7.1.4.1.1 US RNA Based Therapeutic Market by Type
7.1.4.1.2 US RNA Based Therapeutic Market by Application
7.1.4.1.3 US RNA Based Therapeutic Market by End User
7.1.4.2 Canada RNA Based Therapeutic Market
7.1.4.2.1 Canada RNA Based Therapeutic Market by Type
7.1.4.2.2 Canada RNA Based Therapeutic Market by Application
7.1.4.2.3 Canada RNA Based Therapeutic Market by End User
7.1.4.3 Mexico RNA Based Therapeutic Market
7.1.4.3.1 Mexico RNA Based Therapeutic Market by Type
7.1.4.3.2 Mexico RNA Based Therapeutic Market by Application
7.1.4.3.3 Mexico RNA Based Therapeutic Market by End User
7.1.4.4 Rest of North America RNA Based Therapeutic Market
7.1.4.4.1 Rest of North America RNA Based Therapeutic Market by Type
7.1.4.4.2 Rest of North America RNA Based Therapeutic Market by Application
7.1.4.4.3 Rest of North America RNA Based Therapeutic Market by End User
7.2 Europe RNA Based Therapeutic Market
7.2.1 Europe RNA Based Therapeutic Market by Type
7.2.1.1 Europe RNA Antisense Market by Country
7.2.1.2 Europe RNA Interference (RNAi) Market by Country
7.2.2 Europe RNA Based Therapeutic Market by Application
7.2.2.1 Europe Genetic disorders Market by Country
7.2.2.2 Europe Auto immune disorders Market by Country
7.2.3 Europe RNA Based Therapeutic Market by End User
7.2.3.1 Europe Research Institutes Market by Country
7.2.3.2 Europe Hospitals & Clinics Market by Country
7.2.4 Europe RNA Based Therapeutic Market by Country
7.2.4.1 Germany RNA Based Therapeutic Market
7.2.4.1.1 Germany RNA Based Therapeutic Market by Type
7.2.4.1.2 Germany RNA Based Therapeutic Market by Application
7.2.4.1.3 Germany RNA Based Therapeutic Market by End User
7.2.4.2 UK RNA Based Therapeutic Market
7.2.4.2.1 UK RNA Based Therapeutic Market by Type
7.2.4.2.2 UK RNA Based Therapeutic Market by Application
7.2.4.2.3 UK RNA Based Therapeutic Market by End User
7.2.4.3 France RNA Based Therapeutic Market
7.2.4.3.1 France RNA Based Therapeutic Market by Type
7.2.4.3.2 France RNA Based Therapeutic Market by Application
7.2.4.3.3 France RNA Based Therapeutic Market by End User
7.2.4.4 Russia RNA Based Therapeutic Market
7.2.4.4.1 Russia RNA Based Therapeutic Market by Type
7.2.4.4.2 Russia RNA Based Therapeutic Market by Application
7.2.4.4.3 Russia RNA Based Therapeutic Market by End User
7.2.4.5 Spain RNA Based Therapeutic Market
7.2.4.5.1 Spain RNA Based Therapeutic Market by Type
7.2.4.5.2 Spain RNA Based Therapeutic Market by Application
7.2.4.5.3 Spain RNA Based Therapeutic Market by End User
7.2.4.6 Italy RNA Based Therapeutic Market
7.2.4.6.1 Italy RNA Based Therapeutic Market by Type
7.2.4.6.2 Italy RNA Based Therapeutic Market by Application
7.2.4.6.3 Italy RNA Based Therapeutic Market by End User
7.2.4.7 Rest of Europe RNA Based Therapeutic Market
7.2.4.7.1 Rest of Europe RNA Based Therapeutic Market by Type
7.2.4.7.2 Rest of Europe RNA Based Therapeutic Market by Application
7.2.4.7.3 Rest of Europe RNA Based Therapeutic Market by End User
7.3 Asia Pacific RNA Based Therapeutic Market
7.3.1 Asia Pacific RNA Based Therapeutic Market by Type
7.3.1.1 Asia Pacific RNA Antisense Market by Country
7.3.1.2 Asia Pacific RNA Interference (RNAi) Market by Country
7.3.2 Asia Pacific RNA Based Therapeutic Market by Application
7.3.2.1 Asia Pacific Genetic disorders Market by Country
7.3.2.2 Asia Pacific Auto immune disorders Market by Country
7.3.3 Asia Pacific RNA Based Therapeutic Market by End User
7.3.3.1 Asia Pacific Research Institutes Market by Country
7.3.3.2 Asia Pacific Hospitals & Clinics Market by Country
7.3.4 Asia Pacific RNA Based Therapeutic Market by Country
7.3.4.1 China RNA Based Therapeutic Market
7.3.4.1.1 China RNA Based Therapeutic Market by Type
7.3.4.1.2 China RNA Based Therapeutic Market by Application
7.3.4.1.3 China RNA Based Therapeutic Market by End User
7.3.4.2 Japan RNA Based Therapeutic Market
7.3.4.2.1 Japan RNA Based Therapeutic Market by Type
7.3.4.2.2 Japan RNA Based Therapeutic Market by Application
7.3.4.2.3 Japan RNA Based Therapeutic Market by End User
7.3.4.3 India RNA Based Therapeutic Market
7.3.4.3.1 India RNA Based Therapeutic Market by Type
7.3.4.3.2 India RNA Based Therapeutic Market by Application
7.3.4.3.3 India RNA Based Therapeutic Market by End User
7.3.4.4 South Korea RNA Based Therapeutic Market
7.3.4.4.1 South Korea RNA Based Therapeutic Market by Type
7.3.4.4.2 South Korea RNA Based Therapeutic Market by Application
7.3.4.4.3 South Korea RNA Based Therapeutic Market by End User
7.3.4.5 Singapore RNA Based Therapeutic Market
7.3.4.5.1 Singapore RNA Based Therapeutic Market by Type
7.3.4.5.2 Singapore RNA Based Therapeutic Market by Application
7.3.4.5.3 Singapore RNA Based Therapeutic Market by End User
7.3.4.6 Malaysia RNA Based Therapeutic Market
7.3.4.6.1 Malaysia RNA Based Therapeutic Market by Type
7.3.4.6.2 Malaysia RNA Based Therapeutic Market by Application
7.3.4.6.3 Malaysia RNA Based Therapeutic Market by End User
7.3.4.7 Rest of Asia Pacific RNA Based Therapeutic Market
7.3.4.7.1 Rest of Asia Pacific RNA Based Therapeutic Market by Type
7.3.4.7.2 Rest of Asia Pacific RNA Based Therapeutic Market by Application
7.3.4.7.3 Rest of Asia Pacific RNA Based Therapeutic Market by End User
7.4 LAMEA RNA Based Therapeutic Market
7.4.1 LAMEA RNA Based Therapeutic Market by Type
7.4.1.1 LAMEA RNA Antisense Market by Country
7.4.1.2 LAMEA RNA Interference (RNAi) Market by Country
7.4.2 LAMEA RNA Based Therapeutic Market by Application
7.4.2.1 LAMEA Genetic disorders Market by Country
7.4.2.2 LAMEA Auto immune disorders Market by Country
7.4.3 LAMEA RNA Based Therapeutic Market by End User
7.4.3.1 LAMEA Research Institutes Market by Country
7.4.3.2 LAMEA Hospitals & Clinics Market by Country
7.4.4 LAMEA RNA Based Therapeutic Market by Country
7.4.4.1 Brazil RNA Based Therapeutic Market
7.4.4.1.1 Brazil RNA Based Therapeutic Market by Type
7.4.4.1.2 Brazil RNA Based Therapeutic Market by Application
7.4.4.1.3 Brazil RNA Based Therapeutic Market by End User
7.4.4.2 Argentina RNA Based Therapeutic Market
7.4.4.2.1 Argentina RNA Based Therapeutic Market by Type
7.4.4.2.2 Argentina RNA Based Therapeutic Market by Application
7.4.4.2.3 Argentina RNA Based Therapeutic Market by End User
7.4.4.3 UAE RNA Based Therapeutic Market
7.4.4.3.1 UAE RNA Based Therapeutic Market by Type
7.4.4.3.2 UAE RNA Based Therapeutic Market by Application
7.4.4.3.3 UAE RNA Based Therapeutic Market by End User
7.4.4.4 Saudi Arabia RNA Based Therapeutic Market
7.4.4.4.1 Saudi Arabia RNA Based Therapeutic Market by Type
7.4.4.4.2 Saudi Arabia RNA Based Therapeutic Market by Application
7.4.4.4.3 Saudi Arabia RNA Based Therapeutic Market by End User
7.4.4.5 South Africa RNA Based Therapeutic Market
7.4.4.5.1 South Africa RNA Based Therapeutic Market by Type
7.4.4.5.2 South Africa RNA Based Therapeutic Market by Application
7.4.4.5.3 South Africa RNA Based Therapeutic Market by End User
7.4.4.6 Nigeria RNA Based Therapeutic Market
7.4.4.6.1 Nigeria RNA Based Therapeutic Market by Type
7.4.4.6.2 Nigeria RNA Based Therapeutic Market by Application
7.4.4.6.3 Nigeria RNA Based Therapeutic Market by End User
7.4.4.7 Rest of LAMEA RNA Based Therapeutic Market
7.4.4.7.1 Rest of LAMEA RNA Based Therapeutic Market by Type
7.4.4.7.2 Rest of LAMEA RNA Based Therapeutic Market by Application
7.4.4.7.3 Rest of LAMEA RNA Based Therapeutic Market by End User

Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:

TABLE 1 Global RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 2 Global RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– RNA Based Therapeutic Market
TABLE 4 Acquisition and Mergers– RNA Based Therapeutic Market
TABLE 5 Approvals and trials– RNA Based Therapeutic Market
TABLE 6 Global RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 7 Global RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 8 Global RNA Antisense Market by Region, 2017 - 2020, USD Million
TABLE 9 Global RNA Antisense Market by Region, 2021 - 2027, USD Million
TABLE 10 Global RNA Interference (RNAi) Market by Region, 2017 - 2020, USD Million
TABLE 11 Global RNA Interference (RNAi) Market by Region, 2021 - 2027, USD Million
TABLE 12 Global RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 13 Global RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 14 Global Genetic disorders Market by Region, 2017 - 2020, USD Million
TABLE 15 Global Genetic disorders Market by Region, 2021 - 2027, USD Million
TABLE 16 Global Auto immune disorders Market by Region, 2017 - 2020, USD Million
TABLE 17 Global Auto immune disorders Market by Region, 2021 - 2027, USD Million
TABLE 18 Global RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 19 Global RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 20 Global Research Institutes Market by Region, 2017 - 2020, USD Million
TABLE 21 Global Research Institutes Market by Region, 2021 - 2027, USD Million
TABLE 22 Global Hospitals & Clinics Market by Region, 2017 - 2020, USD Million
TABLE 23 Global Hospitals & Clinics Market by Region, 2021 - 2027, USD Million
TABLE 24 Global RNA Based Therapeutic Market by Region, 2017 - 2020, USD Million
TABLE 25 Global RNA Based Therapeutic Market by Region, 2021 - 2027, USD Million
TABLE 26 North America RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 27 North America RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 28 North America RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 29 North America RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 30 North America RNA Antisense Market by Country, 2017 - 2020, USD Million
TABLE 31 North America RNA Antisense Market by Country, 2021 - 2027, USD Million
TABLE 32 North America RNA Interference (RNAi) Market by Country, 2017 - 2020, USD Million
TABLE 33 North America RNA Interference (RNAi) Market by Country, 2021 - 2027, USD Million
TABLE 34 North America RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 35 North America RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 36 North America Genetic disorders Market by Country, 2017 - 2020, USD Million
TABLE 37 North America Genetic disorders Market by Country, 2021 - 2027, USD Million
TABLE 38 North America Auto immune disorders Market by Country, 2017 - 2020, USD Million
TABLE 39 North America Auto immune disorders Market by Country, 2021 - 2027, USD Million
TABLE 40 North America RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 41 North America RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 42 North America Research Institutes Market by Country, 2017 - 2020, USD Million
TABLE 43 North America Research Institutes Market by Country, 2021 - 2027, USD Million
TABLE 44 North America Hospitals & Clinics Market by Country, 2017 - 2020, USD Million
TABLE 45 North America Hospitals & Clinics Market by Country, 2021 - 2027, USD Million
TABLE 46 North America RNA Based Therapeutic Market by Country, 2017 - 2020, USD Million
TABLE 47 North America RNA Based Therapeutic Market by Country, 2021 - 2027, USD Million
TABLE 48 US RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 49 US RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 50 US RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 51 US RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 52 US RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 53 US RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 54 US RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 55 US RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 56 Canada RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 57 Canada RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 58 Canada RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 59 Canada RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 60 Canada RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 61 Canada RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 62 Canada RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 63 Canada RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 64 Mexico RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 65 Mexico RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 66 Mexico RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 67 Mexico RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 68 Mexico RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 69 Mexico RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 70 Mexico RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 71 Mexico RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 72 Rest of North America RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 73 Rest of North America RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 74 Rest of North America RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 75 Rest of North America RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 76 Rest of North America RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 77 Rest of North America RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 78 Rest of North America RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 79 Rest of North America RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 80 Europe RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 81 Europe RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 82 Europe RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 83 Europe RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 84 Europe RNA Antisense Market by Country, 2017 - 2020, USD Million
TABLE 85 Europe RNA Antisense Market by Country, 2021 - 2027, USD Million
TABLE 86 Europe RNA Interference (RNAi) Market by Country, 2017 - 2020, USD Million
TABLE 87 Europe RNA Interference (RNAi) Market by Country, 2021 - 2027, USD Million
TABLE 88 Europe RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 89 Europe RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 90 Europe Genetic disorders Market by Country, 2017 - 2020, USD Million
TABLE 91 Europe Genetic disorders Market by Country, 2021 - 2027, USD Million
TABLE 92 Europe Auto immune disorders Market by Country, 2017 - 2020, USD Million
TABLE 93 Europe Auto immune disorders Market by Country, 2021 - 2027, USD Million
TABLE 94 Europe RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 95 Europe RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 96 Europe Research Institutes Market by Country, 2017 - 2020, USD Million
TABLE 97 Europe Research Institutes Market by Country, 2021 - 2027, USD Million
TABLE 98 Europe Hospitals & Clinics Market by Country, 2017 - 2020, USD Million
TABLE 99 Europe Hospitals & Clinics Market by Country, 2021 - 2027, USD Million
TABLE 100 Europe RNA Based Therapeutic Market by Country, 2017 - 2020, USD Million
TABLE 101 Europe RNA Based Therapeutic Market by Country, 2021 - 2027, USD Million
TABLE 102 Germany RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 103 Germany RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 104 Germany RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 105 Germany RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 106 Germany RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 107 Germany RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 108 Germany RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 109 Germany RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 110 UK RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 111 UK RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 112 UK RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 113 UK RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 114 UK RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 115 UK RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 116 UK RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 117 UK RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 118 France RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 119 France RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 120 France RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 121 France RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 122 France RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 123 France RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 124 France RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 125 France RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 126 Russia RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 127 Russia RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 128 Russia RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 129 Russia RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 130 Russia RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 131 Russia RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 132 Russia RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 133 Russia RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 134 Spain RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 135 Spain RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 136 Spain RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 137 Spain RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 138 Spain RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 139 Spain RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 140 Spain RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 141 Spain RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 142 Italy RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 143 Italy RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 144 Italy RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 145 Italy RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 146 Italy RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 147 Italy RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 148 Italy RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 149 Italy RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 150 Rest of Europe RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 151 Rest of Europe RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 152 Rest of Europe RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 153 Rest of Europe RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 154 Rest of Europe RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 155 Rest of Europe RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 156 Rest of Europe RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 157 Rest of Europe RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 158 Asia Pacific RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 159 Asia Pacific RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 160 Asia Pacific RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 161 Asia Pacific RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 162 Asia Pacific RNA Antisense Market by Country, 2017 - 2020, USD Million
TABLE 163 Asia Pacific RNA Antisense Market by Country, 2021 - 2027, USD Million
TABLE 164 Asia Pacific RNA Interference (RNAi) Market by Country, 2017 - 2020, USD Million
TABLE 165 Asia Pacific RNA Interference (RNAi) Market by Country, 2021 - 2027, USD Million
TABLE 166 Asia Pacific RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 167 Asia Pacific RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 168 Asia Pacific Genetic disorders Market by Country, 2017 - 2020, USD Million
TABLE 169 Asia Pacific Genetic disorders Market by Country, 2021 - 2027, USD Million
TABLE 170 Asia Pacific Auto immune disorders Market by Country, 2017 - 2020, USD Million
TABLE 171 Asia Pacific Auto immune disorders Market by Country, 2021 - 2027, USD Million
TABLE 172 Asia Pacific RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 173 Asia Pacific RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 174 Asia Pacific Research Institutes Market by Country, 2017 - 2020, USD Million
TABLE 175 Asia Pacific Research Institutes Market by Country, 2021 - 2027, USD Million
TABLE 176 Asia Pacific Hospitals & Clinics Market by Country, 2017 - 2020, USD Million
TABLE 177 Asia Pacific Hospitals & Clinics Market by Country, 2021 - 2027, USD Million
TABLE 178 Asia Pacific RNA Based Therapeutic Market by Country, 2017 - 2020, USD Million
TABLE 179 Asia Pacific RNA Based Therapeutic Market by Country, 2021 - 2027, USD Million
TABLE 180 China RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 181 China RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 182 China RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 183 China RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 184 China RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 185 China RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 186 China RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 187 China RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 188 Japan RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 189 Japan RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 190 Japan RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 191 Japan RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 192 Japan RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 193 Japan RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 194 Japan RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 195 Japan RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 196 India RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 197 India RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 198 India RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 199 India RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 200 India RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 201 India RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 202 India RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 203 India RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 204 South Korea RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 205 South Korea RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 206 South Korea RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 207 South Korea RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 208 South Korea RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 209 South Korea RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 210 South Korea RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 211 South Korea RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 212 Singapore RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 213 Singapore RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 214 Singapore RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 215 Singapore RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 216 Singapore RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 217 Singapore RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 218 Singapore RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 219 Singapore RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 220 Malaysia RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 221 Malaysia RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 222 Malaysia RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 223 Malaysia RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 224 Malaysia RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 225 Malaysia RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 226 Malaysia RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 227 Malaysia RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 228 Rest of Asia Pacific RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 229 Rest of Asia Pacific RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 230 Rest of Asia Pacific RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 231 Rest of Asia Pacific RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 232 Rest of Asia Pacific RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 233 Rest of Asia Pacific RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 234 Rest of Asia Pacific RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 235 Rest of Asia Pacific RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 236 LAMEA RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 237 LAMEA RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 238 LAMEA RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 239 LAMEA RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 240 LAMEA RNA Antisense Market by Country, 2017 - 2020, USD Million
TABLE 241 LAMEA RNA Antisense Market by Country, 2021 - 2027, USD Million
TABLE 242 LAMEA RNA Interference (RNAi) Market by Country, 2017 - 2020, USD Million
TABLE 243 LAMEA RNA Interference (RNAi) Market by Country, 2021 - 2027, USD Million
TABLE 244 LAMEA RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 245 LAMEA RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 246 LAMEA Genetic disorders Market by Country, 2017 - 2020, USD Million
TABLE 247 LAMEA Genetic disorders Market by Country, 2021 - 2027, USD Million
TABLE 248 LAMEA Auto immune disorders Market by Country, 2017 - 2020, USD Million
TABLE 249 LAMEA Auto immune disorders Market by Country, 2021 - 2027, USD Million
TABLE 250 LAMEA RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 251 LAMEA RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 252 LAMEA Research Institutes Market by Country, 2017 - 2020, USD Million
TABLE 253 LAMEA Research Institutes Market by Country, 2021 - 2027, USD Million
TABLE 254 LAMEA Hospitals & Clinics Market by Country, 2017 - 2020, USD Million
TABLE 255 LAMEA Hospitals & Clinics Market by Country, 2021 - 2027, USD Million
TABLE 256 LAMEA RNA Based Therapeutic Market by Country, 2017 - 2020, USD Million
TABLE 257 LAMEA RNA Based Therapeutic Market by Country, 2021 - 2027, USD Million
TABLE 258 Brazil RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 259 Brazil RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 260 Brazil RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 261 Brazil RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 262 Brazil RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 263 Brazil RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 264 Brazil RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 265 Brazil RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 266 Argentina RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 267 Argentina RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 268 Argentina RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 269 Argentina RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 270 Argentina RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 271 Argentina RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 272 Argentina RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 273 Argentina RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 274 UAE RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 275 UAE RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 276 UAE RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 277 UAE RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 278 UAE RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 279 UAE RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 280 UAE RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 281 UAE RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 282 Saudi Arabia RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 283 Saudi Arabia RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 284 Saudi Arabia RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 285 Saudi Arabia RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 286 Saudi Arabia RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 287 Saudi Arabia RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 288 Saudi Arabia RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 289 Saudi Arabia RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 290 South Africa RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 291 South Africa RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 292 South Africa RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 293 South Africa RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 294 South Africa RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 295 South Africa RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 296 South Africa RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 297 South Africa RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 298 Nigeria RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 299 Nigeria RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 300 Nigeria RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 301 Nigeria RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 302 Nigeria RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 303 Nigeria RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 304 Nigeria RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 305 Nigeria RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 306 Rest of LAMEA RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 307 Rest of LAMEA RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 308 Rest of LAMEA RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 309 Rest of LAMEA RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 310 Rest of LAMEA RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 311 Rest of LAMEA RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 312 Rest of LAMEA RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 313 Rest of LAMEA RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 314 Key information – Arbutus Biopharma Corporation
TABLE 315 Key information – Arrowhead Pharmaceuticals, Inc.
TABLE 316 Key information – Benitec Biopharma, Inc.
TABLE 317 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 318 Key Information – Sanofi S.A.
TABLE 319 Key Information – Biogen, Inc.
TABLE 320 Key information – Gradalis, Inc.
TABLE 321 Key information – Ionis Pharmaceuticals, Inc.
TABLE 322 Key information – Sarepta Therapeutics, Inc.
TABLE 323 Key information – Silence Therapeutics plc

List of Figures
FIG 1 Methodology for the research
FIG 1 KBV Cardinal Matrix
FIG 2 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 3 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
FIG 4 Recent strategies and developments: Arbutus Biopharma Corporation
FIG 5 Recent strategies and developments: Sanofi S.A.